Cancer drug maker takes sudden pivot into crypto

A cancer drug developer has rocked Wall Street by implementing what is perhaps the most audacious crypto treasury strategy we have seen from a traditional biotech firm. MAIA Biotechnology (NYSE American: MAIA) announced on October 7 that its Board of Directors has approved allocating up to 90% of the company's liquid assets into cryptocurrencies, including Bitcoin (BTC), Ethereum (ETH), and USD Coin (USDC) for now. Following the news of this move, the stock increased more than 4% intraday. The stock rose ...